purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation earnings call period ending march image source motley fool abbott laboratory q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning thank standing welcome abbotts firstquarter earnings conference call operator instruction call recorded abbott exception participant question asked questionandanswer session entire call including questionandanswer session material copyrighted abbott recorded rebroadcast without abbotts expressed written permission would like introduce mr mike comilla vice president investor relationsmike comilla vice president investor relation good morning thank joining u today robert ford chairman chief executive officer bob funck executive vice president finance phil boudreau senior vice president finance chief financial officer robert phil provide opening remark following comment take question get started statement made today may forwardlooking purpose private security litigation reform act including expected financial result abbott caution forwardlooking statement subject risk uncertainty may cause actual result differ materially indicated forwardlooking statement economic competitive governmental technological factor may affect abbotts operation discussed item risk factor annual report form k year ended december st abbott undertakes obligation release publicly revision forwardlooking statement result subsequent event development except required lawon today conference call past nongaap financial measure used help investor understand abbotts ongoing business performance nongaap financial measure reconciled comparable gaap financial measure earnings news release regulatory filing today available website abbottcom note abbott provided gaap financial measure organic sale growth forwardlooking basis company unable predict future change foreign exchange rate could impact reported sale growth unless otherwise noted commentary sale growth refers organic sale growth defined press release issued earlier today turn call robert robert ford chairman chief executive officer thanks mike good morning everyone thank joining u today reported firstquarter adjusted earnings per share analyst consensus estimate also raised midpoint guidance range earnings per share sale growth forecast fullyear adjusted earnings per share organic sale growth excluded covid testing related sale organic sale growth excluding covid testing related sale quarter represents fifth consecutive quarter doubledigit growth strong start year driven broad base growth across portfolio including growth medical device established pharmaceutical addition exceeding expectation top bottom line quarter accomplished number objective across pipeline including obtaining several new product approval achieving important clinical trial related milestone summarize firstquarter result detail turning coal phil start nutrition sale increased quarter strong growth quarter led doubledigit growth pediatric nutrition driven continued market share gain yous infant formula business growth across international portfolio infant formula toddler adult nutrition brand january launched new nutrition shake called protality provides nutritional support adult pursuing weight loss people eat le lose weight taking glp medication undergoing weight loss surgery following calorie restricted diet portion lost lean muscle mass play important role overall health combination high protein essential vitamin mineral totality offer help people preserve muscle pursuing personal weight loss goal turning epd sale increased quarter quarter continuation epds impressive trend strong performance including doubledigit growth four last five quarter addition strong track record topline growth business delivered equally impressive gain bottom line operating margin profile last year reflected basis point improvement compared moving diagnostics sale increased excluding covid testing sale growth diagnostics continues led adoption market leading system demand testing take place variety setting including hospital laboratory urgent care center physician office retail pharmacy blood screening facility development effort diagnostics focus developing new system creating new test play important role making healthcare decision expand accessibility testing deliver result fast possible april received fda approval point care diagnostic test could help determine someone suffered mild traumatic brain injury concussion minute test run portable istat alinity instrument allows concussion testing move beyond traditional hospital setting urgent care center physician office location closer patient nearly million people yous going emergency room checked suspected concussion year believe test potential transform standard care concussion testing wrap medical device sale grew diabetes care freestyle libre sale billion quarter grew previously mentioned libre several new growth opportunity help continue fuel strong sale trajectory forecasted one growth opportunity relates continued expansion reimbursement coverage libre individual use basal insulin therapy manage diabetes last year announced libre became first continuous glucose monitoring system nationally reimbursed france include people use basal insulin part diabetes management first quarter libre obtained reimbursement select number institutional payer germany basal insulin user also use oral diabetes medication manage condition select public private payer cover limited number approximately million basal insulin user germany encouraging sign potential coverage expansion germany across european market cardiovascular device sale grew overall quarter led doubledigit growth electrophysiology structural heart continued acceleration cardiac rhythm management vascular portfolio electrophysiology sale grew driven doubledigit growth major geographic region across major product category including doubledigit growth ablation catheter cardiac mapping related product continue make great progress toward bringing innovative pfa catheter volt market march completed enrollment ce mark clinical study putting u track file international approval end year also recently began enrolling patient yous clinical trial called voltaf generate data needed support fda approval filing structural heart growth led strong performance several highgrowth area including tavr laa mitral tricuspid repair structural heart area invested past year order create diversified portfolio sustainably deliver doubledigit growth past relied almost exclusively mitraclip drive growth today portfolio growth balanced reflect increasing contribution newer product like navitor amulet triclip april received fda approval triclip first kind heart valve repair device designed treatment tricuspid regurgitation leaky tricuspid valve data clinical trial supporting approval demonstrated patient receive triclip experienced significant improvement severity symptom quality life excited offer lifechanging treatment option people united state suffer condition rhythm management growth led aveir recently launched leadless pacemaker aveir rapidly captured market share single chamber pacing segment market used dual chamber pacing largest segment pacing market revolutionary technology helping deliver growth rate rhythm management business significantly exceed overall growth market lastly neuromodulation sale grew driven eterna rechargeable neurostimulation device pain management january announced launch liberta world smallest rechargeable deep brain stimulation device used treat movement disorder parkinson disease summary good start year exceeding expectation top bottom line result raised midpoint sale eps guidance range continue make good progress gross margin expansion initiative seeing strong return investment making across growth platform pipeline continued highly productive delivering several recently new product approval wellpositioned continue deliver strong result remainder year turn call philphil boudreau senior vice president finance chief financial officer thanks robert mike mentioned earlier please note reference sale growth rate unless otherwise noted organic basis turning firstquarter result sale increased organic basis expected includes impact yearoveryear decline covid testingrelated sale excluding covid testing sale underlying base business organic sale growth quarter foreign exchange unfavorable yearoveryear impact firstquarter sale quarter saw yous dollar strengthen versus several currency resulted exchange unfavorable impact sale compared exchange rate time earnings call january regarding aspect pl adjusted gross margin ratio sale adjusted rd sale adjusted sga sale first quarter lastly firstquarter adjusted tax rate turning outlook full year forecast fullyear adjusted earnings per share represents increase midpoint range compared guidance range provided january also raised midpoint guidance organic sale growth forecast organic sale growth excluding covid testing range based current rate expect exchange unfavorable impact approximately fullyear reported sale includes expected unfavorable impact approximately secondquarter reported sale lastly second quarter forecast adjusted earnings per share open call question question answer operatorthank operator instruction first question come robbie marcus jp morgan line openrobbie marcus jpmorgan chase company analyst great thanks taking question congrats nice first quarter two ask upfront first robert almost never see abbott raise guidance particularly top line first quarter looking back past know five year rare first part gave confidence raise midpoint guidance early year second obviously lot concern quarter competitor loss case nec relates infant nutrition hoping could address stance ongoing litigation think thousand case filed upcoming data point timeline looking forrobert ford chairman chief executive officer let u go first question guidance yeah right guess go back take look think last time raise q would say framework rob always done set guidance beginning year believe top tier throughout year want beat guidance consider top tier high singledigit doubledigit eps growth obviously excluding covid testing portion investor really focused guidance set couple month ago back january target always toptier guidance find appropriate balance opportunity obviously challenge bracket range remember january said thought opportunity risk think risk saw january still think gone away still whether geopolitics whether fx still clearly performance business continues strong business lot business actually accelerating performance said comment five consecutive quarter doubledigit growth look business epd consecutive three consecutive doubledigit growth great margin expansion team working able introduce biosimilars market participating nutrition done incredible job recovering share growing adult business grown adult billion versus diagnostics continues great track record outperforming market got great large account win yous internationally rolling year medical device mean tell real strong performer team done incredible job last year fastestgrowing medtech company least seen guidance guidance market seems year put together plus pipeline contributing accelerated level great new product approval put together feel type performance deliver give u confidence remainder outlook year felt comfortable raising guidance first quarter pointed something usually continue believe going second quarter move probably opportunity risk move forward guess framework raising guidance first quarter something usually great performance great momentum question regarding net case would say date court case happen july maybe milestone want look asking kind framework look would say decade provided specialized nutrition product help doctor think key thing help doctor provide lifesaving nutrition premature infant feed premature infant medical decision robbie health care provider going use range option meet unique need baby includes mother milk includes pasteurized donor milk also includes preterm infant formula mother milk available sufficient supply donor milk satisfy nutritional need premature infant born yous quite frankly even available premature infant human milk may lack calorie protein vitamin etc necessary support nutritional need premature infant mother milk need fortified order boost nutritional output medical community consider product critical part standard care feeding premature infant society read position standard care use product doctor work nicu used product decade continue today countless baby robbie benefited product lifesaving experience many many year clinical study repeatedly established product safe litigation case really seeking advance theory promoted plenty lawyer distorts science distorts everything know supported medical community preparing case able kind lay fact science data stand behind productsrobbie marcus jpmorgan chase company analyst appreciate robert thanks lotoperatorthank next question come larry biegelsen fargo line openlarry biegelsen well fargo security analyst good morning echo robbies congratulation strong start year robert wanted focus ep multipart question one ep business grew nicely first quarter yous outside yous talk drove seeing pfa different geography expectation ep business going forward volt launch lastly sound like expect volt approval europe sometime next year based filing date want confirm thatrobert ford chairman chief executive officer sure like said opening comment completed trial sixmonth followup larry mean target file ce mark end year going depend process think probably anchor point getting filing end year yes mean surprised ep growth know many call might surprised first important therapy underpenetrated disease know plenty growth segment result highly competitive surprised growth look pfa europe three year average growth rate last three year europe growing midteens growth remains broad base broad based europe quarter saw doubledigit growth ablation catheter mapping side ablation catheter side also also great growth mapping side technology come yous think probably maybe two month seeing technology rolled yous think competitor aggressive term bringing technology account yous say mapped lot case larry going say every single case would say vast majority case similarity europe difference europe think one thing saw europe inclination use technology starting kind one shot impact cryo business would say rf side saw mapping case saw least first couple month large portion case occurred least one mapped place traditionally used cryo think difference saw little bit europe least case part direct indirectly using mapping number lower europe probably little bit difference saw yous bodes well u end site system mapping system mapping catheter widely viewed excellent option mapping pfa case large install base customer familiar need make room need fight capital got bestinclass clinical support architecture open said previous call integrates well pfa catheter actually recently released software upgrade last month provides even better visualization catheter potential faster procedure le floor time think perfect combination quite frankly time going market transition lot new product lot choice situation like think flexibility key heard customer one data point thought also interesting question helped drive case part saw also observed rf catheter pulled quarter case saw top pfa catheter rf catheter pulled touchups etc would say right everything seen europe positive side happening think interesting dynamic yous could favorable u also still early look march probably one look case per day probably one highest month far good excited technology excited program released data program recent medical meeting occurred feedback used product positive integration ensite including like tissue contact force algorithm visualization seen real promise differentiator versus used todaylarry biegelsen well fargo security analyst thanks muchoperatorthank next question come josh jennings cowen line openjosh jennings td cowen analyst good morning thanks taking question great see strong start q result robert hoping ask first libre internationally payment coverage decision radar various country sound like made sense nice progress already germany yous hoping could help share thought share gain opportunity integrated pump segment cgm market versus share loss risk type noninsulin cash pace segment competitive launch share early one followuprobert ford chairman chief executive officer international question mean always difficult forecast exactly monthaquarter coverage kind payment decision tell though team full global map work done regarding clinical information negotiation etc difficult kind forecast said previous call prepared remark think going see build occurring globally market data prof show clinical medical health economic benefit reimbursing patient population think wellpositioned internationally think got pretty large market already canada japan france italy germany market either fully reimbursed starting process like said think see year progress whether medical event year progress think see coverage decision maybe get splashy big pr news seeing continuous increasing yous side guess disagree premise going trading share gain pump side share loss noninsulin side mean right looking data third party audited data seven every new prescription basal population primarily served primary care channel seven going libre think product going get even competitive compelling think great opportunity objective maintain kind shared dominance share leadership result patient segment opportunity participate little bit actively little bit smaller segment population nonetheless important one aid market system new start year opportunity share gain also existing user think opportunity bring dual analyte sensor ketone showed data attd year showed safety benefit value proposition dual analyte sensor aid system think going compelling value proposition working pump company think year progress see connectivity occur whether libre plus streaming product whether libre area focusing new segment u compete think going taking eye ball relates basal opportunity existsjosh jennings td cowen analyst understood thanks wanted ask transcatheter tricuspid market congratulation triclip approval question around patient opportunity breakdown tier triclip replacement evoque maybe internal team thought patient opportunity breakdown maybe could share pricing strategy triclip setting competitor pricing replacement device significant premium thanks taking questionsrobert ford chairman chief executive officer going comment pricing strategy competitive reason differentiated novel technology opportunity see play got ntap submission stuff going right focused launching product getting case ramped happening got feedback yesterday team couple week real nice cadence growth obviously focusing initial case account part pivotal trial real nice cadence growth great feedback physician patient postsurgery mean trying poke breakdown going replace repair listen think good option guess view believe probably safety key driver start think triclip shown strong excellent safety record clinical trial real world use think going play key role determining repair versus replace expect repair triclip least preferred option unless valve damaged obviously replacement option large pool patient got million people globally million people yous going opportunity generating data expand indication product think easily billion opportunity u build capability build clinical datajosh jennings td cowen analyst excellent thank youoperatorthank next question come travis steed bofa security line opentravis steed bank america merrill lynch analyst hey congrats good quarter maybe pipeline talk little bit aveir sound like product going really well question gross margin well trying think right pace kind get back precovid level still opportunity kind longer term gross marginsrobert ford chairman chief executive officer think aveirs done well mean know advantage competitive system whether single dual chamber longer lasting battery ability replacement retrievability upgradeability done well single chamber perspective think share u market well performed started dual chamber procedure toward end last year seeing nice kind rampup first quarter focus really really completely different procedure right think device implanted probably first time like year like real meaningful change done focus really getting great clinical result real thoughtful approach opening new sensor training working well u could see impact growth rate mean historically crm business relatively flat platform going platform going goal program get crm portfolio least contributor growth midsingle digit last couple quarter done seven half percent aveirs well going continue get better physician get trained increase amount account really like cadence forecasting business impact going crm portfolio questiontravis steed bank america merrill lynch analyst gross margin kind thinking path back precovid level long term right kind cadence year cadence right way think thatrobert ford chairman chief executive officer think good cadence think forecasting basis point improvement year feel good talked question question think bad cadence going focus thing control thing control obviously cost cost team team working improving gross margin delivering great result time maintaining high service level running back order etc probably biggest biggest opportunity travis expand gross margin portfolio mix medical device business growing midteens consistently last whatever four five quarter real strong impact gross margin lot focus control gross margin cadence targeting really question question whentravis steed bank america merrill lynch analyst great thanks lot congrats againoperatorthank next question come vijay kumar evercore isi line openvijay kumar evercore isi analyst hey guy thanks taking question robert two forward question lot question pipeline curious people ask u sustainability growth could elaborate pipeline else look future give u confidence sustaining premium growth within med tech industry second part financial modeling side look like fx headwind came little bit higher prior guidance headwind eps fx increase curious question high end guidance raised suspect fx headwind increaserobert ford chairman chief executive officer said certain challenge still remain u january fx one let phil answer one question pipeline listen could spend whole hour going pipeline guess would bucket like three category vijay would say got current contributor libre alinity still operate like pipeline project product still got multiple innovation going mitraclip great familiarity aveir navitor triclip amulet protality concussion test think got great opportunity cardiomems mean product would still characterize early inning yes established still early inning got lot growth rate second group product would call probably nearterm future contributor think next month product coming market starting kind generate revenue lingo product excited bringing yous expanding globally dual analyte sensor volt system esprit drug eluding bioabsorbable stent knee first kind developing whole new alinity system target segment market currently participate come great opportunity biosimilars emerging market capital efficient way bringing leveraging position next month kind catalyst thinking beyond mean working pfa rf catheter got leadless another kind leadless pacing system would launching second generation amulet excited entry ivl market sometime coronary dcb working kind new tavr system also allow u branch segment got whole plethora new analytes bio wearable market start come different application top clinical work expand indication expand market whether tavr whether laa whether mitral got would say real nice cadence product pipeline beyond would say next month looking feel really excited obviously need add think base look really good term pipeline think question fx phil want take thatphil boudreau senior vice president finance chief financial officer yes mentioned onset vijay q saw headwind sale growth kind current rate anticipate something similar q fullyear perspective current rate headwind top line said kind earnings guide line organic sale performance drop earnings increased midpoint eps guidancevijay kumar evercore isi analyst thanks guysoperatorthank next question come joanne wuensch citi line openjoanne wuensch citi analyst good morning may add compliment congratulation quarter two question put right front first one concussion testing would love understand gotomarket strategy think financial benefit impact kind good stuff think second question little bit big picture step back postpandemic environment couple year ceo seat think taking abbott sort next level mean sit take look incredibly strong balance sheet put cash work segment division one want keep think adding itrobert ford chairman chief executive officer sure point care concussion test guess would summarize opportunity twofold think market conversion component joanne mentioned million er visit diagnose concussion number one method use ct scan think opportunity transform allow one get faster response emergency kind emergency room visit point care team already good position blood gas assay provide segment think slide right team value proposition going ok cost system bend cost curve think shown little bit think thing joanne look libre look binax look think pricing product come market conversion opportunity able nice return shareholder think important part market expansion opportunity think going still require work product right product approved whole blood venous draw going working capillary draw run assay taking sample finger prick look bringing technology even closer need rapid concussion test would could look many university exist country many high school exist country multiplication say great market creation market expansion opportunity think thinking commercially conversion creation slash expansion work done term product claim trial multiyear kind program start see kind nice growth segment question portfolio balance sheet like four segment answer yes like four segment feel give u real unique view healthcare system whole starting nutrition obviously bedrock good health thing happen need get diagnosis got great diagnostic portfolio expanding building make sure capitalize different type modality location people get tested physician know problem got run treatment right either medicine business medical device business think four segment super well aligned global demographic trend healthcare like always opportunity add shown area feel bring value combination mentioned got strong balance sheet strategic flexibility long feel add value asset felt like csi felt like st jude felt like alere deal obviously help kind reshape company accelerate growth rate think predicated u really believing kind bring value trying fill topline gap issue roic u matter profitability matter got opportunity could little bit selective able add like four segment well shareholder especially longterm shareholdersjoanne wuensch citi analyst thank youoperatorthank next question come matt miksic barclays line openmatt miksic barclays analyst hey good morning thanks putting congrats really strong quarter particularly med device one followup sorry background one question structural heart robert talked little bit portfolio combination leading peer device mitraclip little bit mature category structural heart kind augmented new product like recently obviously triclip could talk little bit sort momentum portfolio well much build portfolio still coming organically review kind strategically appreciate itrobert ford chairman chief executive officer sure mean want comment mitral construed like slowing relying others drive growth mean intent look mitraclip quarter high single digit look last quarter high singledigits low doubledigits good always view attractive area growth attractive area medical need wanted leader yes mitraclip guess call mitraclip founding father structural heart portfolio think team done incredible job bringing organic innovation portfolio look structural heart mean grew today mitraclip grew high single digit accounted growth rest came rest portfolio built think continue see continue make investment business continue make investment pipeline would say right organic whether innovating laa innovating tavr side clinical trial opportunity inorganically put bucket think answered kind joannes question make sense add got flexibility whole strategy say listen going build multibilliondollar structural heart business sustainably grow double digit way division one product think team last four five year done really good job building opportunity would say probably one looking exciting u mitral replacement launched pendine product transapical system cephea system transfemoral transseptal feedback seen early implanters early first man great great valve opportunity also would say organic got capacity inorganic make sensematt miksic barclays analyst thanks muchmike comilla vice president investor relation operator take one question pleaseoperatorthank final question come danielle antalffy ubs line opendanielle antalffy ubs analyst hey good morning everyone thanks much taking question yes congrats strong start year robert spent lot time talking durability growth medtech business want get greedy following joannes question regarding guy strong balance sheet area guess sort feel state med tech business today feel growth area within med tech maybe abbott participating today abbott could participate today looking beyond current market leave onerobert ford chairman chief executive officer sure get attempt triangulation multiple different way guess sign little bit boring term talk public yes interested look area add value would say probably one jumped u term study looking probably medical device side diagnostic side look strategy biosimilars medicine business pretty capital efficient way yes looking continue study going sit telegraph exactly think key thing mean look medtech business quarter look previous four quarter allows little bit selective last couple month seen fairly large transaction medtech space seem attractive growth area talked u getting access early ivl technology csi acquisition important area u focus feel strong organic growth need go pay attention like key financial metric u important term roics got strong growth rate medtech get telegraphing exactly danielle specific segment looking tell active team study lot look lot follow lot moment make sense u segment continue interesting got balance sheet track record show drive value acquisition leave like yes got flexibility mean pay attention key financial return looking feel got strong topline growth great pipeline prospect leave like close saying pleased strong start year delivered another quarter doubledigit organic sale growth base business investment made year covid generating real strong return pipeline continues highly productive outlined got clear visibility pipeline way obtained several new product approval going help u accelerate growth certain area typically raise guidance first quarter given strong performance outlook remainder year felt comfortable wellpositioned continue sustainably deliver toptier result wrap thank joining u todaymike comilla vice president investor relation thank operator thank question concludes abbotts conference call webcast replay call available central time today abbotts investor relation website abbotinvestorcom thank joining u todayoperatoroperator signoff duration minutescall participantsmike comilla vice president investor relationsrobert ford chairman chief executive officerphil boudreau senior vice president finance chief financial officerrobbie marcus jpmorgan chase company analystlarry biegelsen well fargo security analystjosh jennings td cowen analysttravis steed bank america merrill lynch analystvijay kumar evercore isi analystjoanne wuensch citi analystmatt miksic barclays analystdanielle antalffy ubs analyst analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends abbott laboratory motley fool disclosure policy